Evaluation of oil-soluble FUdR ester for transcatheter arterial treatment of hepatomas.
From January 1987 to December 1989, we performed a prospective study of transcatheter arterial chemoembolization therapy with iodized oil (Lipiodol) mixed with an anticancer agent. A new oil-soluble modification of FUdR, FUdR-C8 ester, was developed and dissolved in Lipiodol as an embolic material, which was administered to 36 patients with hepatomas. Water-soluble adriamycin emulsified in Lipiodol was used as control in 67 patients with hepatomas. Initial effects on tumors were observed as decrease of tumor size in 25.0% for the FUdR group and 17.9% for the control group. Alpha-fetoprotein decreased more than half in 41.9% of the FUdR group, and 16.1% of the ADM group. Six-month and one-year survivals were 74.2% and 46.8% for the FUdR group (median survival 317 days), whereas the control group yielded 61.0% and 28.3% survivals, respectively (median survival 191 days).
Yamashita
Y
Y
Department of Radiology, Kumamoto University, School of Medicine, Japan.
Takahashi
M
M
Shinzato
J
J
Bussaka
H
H
Baba
Y
Y
Oguni
T
T
D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D002408:Catheters, Indwelling; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005467:Floxuridine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012995:Solubility
D005467:Floxuridine; D007459:Iodized Oil; D004317:Doxorubicin